Steroid effects on vestibular compensation in human

Neurol Res. 2003 Apr;25(3):287-91. doi: 10.1179/016164103101201364.

Abstract

Vestibular neuritis (VN) rapidly damages unilateral vestibular periphery, inducing severe balance disorders. In most cases, such vestibular imbalance is gradually restored to within the normal level after clinical therapies. This successive clinical recovery occurs due to regeneration of vestibular periphery and/or accomplishment of central vestibular compensation. We experienced 36 patients with VN treated at our hospital, including cases in our previous preliminary report. To elucidate effects of steroid therapy both on the recovery of peripheral function and on the adaptation of central vestibular compensation, we examined caloric test and several questionnaires with two randomly divided groups, 18 steroid-treated and 18 nonsteroid-treated patients, over two years after the onset. These examinations revealed that steroid-treated patients had a tendency of better canal improvements (13/18, 72%) than nonsteroid-treated ones (10/18, 55.6%). However, there was no significant difference between these two groups. In cases with persistent canal paresis, steroid-treated patients (n = 5) reduced handicaps in their everyday life due to the dizziness induced by head and/or body movements and the disturbance of their mood, more effectively than those with nonsteroid therapy (n = 8). These findings suggest that steroid therapy with VN could be effective on not only vestibular periphery but central vestibular system, to restore the balance.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Activities of Daily Living
  • Adolescent
  • Adult
  • Aged
  • Anti-Inflammatory Agents / pharmacology*
  • Caloric Tests
  • Dizziness / drug therapy
  • Female
  • Humans
  • Male
  • Methylprednisolone / pharmacology*
  • Middle Aged
  • Surveys and Questionnaires
  • Treatment Outcome
  • Vestibular Neuronitis / drug therapy*
  • Vestibular Neuronitis / physiopathology*

Substances

  • Anti-Inflammatory Agents
  • Methylprednisolone